Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cost-effectiveness
Pharma
ICER endorses multimillion-dollar hemophilia gene therapies
According to ICER, even at a price tag of $2.5M, oncoming gene therapies can be the most cost-effective therapies for hemophilia patients.
Kevin Dunleavy
Sep 14, 2022 11:38am
AbbVie's Humira tops ICER's list of drug-pricing worst offenders
Nov 16, 2021 8:45am
ICER clears Vertex's Trikafta but blasts 'monopoly' pricing
Sep 23, 2020 11:14am
Roche's Polivy earns NICE nod for lymphoma after early rejection
Aug 20, 2020 11:22am
Sanofi's Sarclisa gets the cold shoulder from NICE
Jun 9, 2020 12:35pm
Merck's Keytruda pulled from England's CDF in bladder cancer
Mar 16, 2020 12:07pm
